Modern Clinical Research on LSD

All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left amygdala reactivity to fearful faces, and enhanced emotional empathy. LSD increased the emotional response to music and the meaning of music. LSD acutely produced deficits in sensorimotor gating, similar to observations in schizophrenia. LSD had weak autonomic stimulant effects and elevated plasma cortisol, prolactin, and oxytocin levels. Resting-state functional magnetic resonance studies showed that LSD acutely reduced the integrity of functional brain networks and increased connectivity between networks that normally are more dissociated. LSD increased functional thalamocortical connectivity and functional connectivity of the primary visual cortex with other brain areas. The latter effect was correlated with subjective hallucinations. LSD acutely induced global increases in brain entropy that were associated with greater trait openness 14 days later. In patients with anxiety associated with life-threatening disease, anxiety was reduced for 2 months after two doses of LSD. In medical settings, no complications of LSD administration were observed. These data should contribute to further investigations of the therapeutic potential of LSD in psychiatry.

[1]  R. Strassman,et al.  Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. , 1994, Archives of general psychiatry.

[2]  D J Nutt,et al.  LSD‐induced entropic brain activity predicts subsequent personality change , 2016, Human brain mapping.

[3]  D. E. Nichols,et al.  Psychedelics as Medicines: An Emerging New Paradigm , 2017, Clinical pharmacology and therapeutics.

[4]  W. Richards,et al.  LSD-assisted psychotherapy with terminal cancer patients. , 1969, Current psychiatric therapies.

[5]  Matthew W. Johnson,et al.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness , 2011, Journal of psychopharmacology.

[6]  C. Grob,et al.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.

[7]  T. S. Krebs,et al.  Over 30 million psychedelic users in the United States , 2013, F1000Research.

[8]  A. Halberstadt Recent advances in the neuropsychopharmacology of serotonergic hallucinogens , 2015, Behavioural Brain Research.

[9]  Robert Leech,et al.  LSD alters eyes‐closed functional connectivity within the early visual cortex in a retinotopic fashion , 2016, Human brain mapping.

[10]  Felix Hasler,et al.  Acute psychological and physiological effects of psilocybin in healthy humans : a double-blind , placebo-controlled dose – effect study , 2004 .

[11]  Christoph Eisenegger,et al.  MDMA enhances emotional empathy and prosocial behavior. , 2014, Social cognitive and affective neuroscience.

[12]  Robert Leech,et al.  Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. , 2013, Schizophrenia bulletin.

[13]  R. A. Sewell,et al.  Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey , 2015, Journal of psychoactive drugs.

[14]  M. Liechti,et al.  In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1 , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[15]  E. Bullmore,et al.  Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution , 2016, Current Biology.

[16]  R. Mowbray,et al.  HALLUCINOGENS , 1970, The Medical journal of Australia.

[17]  A. Young,et al.  Psychedelics in the treatment of unipolar mood disorders: a systematic review , 2016, Journal of psychopharmacology.

[18]  T. S. Krebs,et al.  Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials , 2012, Journal of psychopharmacology.

[19]  Kevin Murphy,et al.  Neural correlates of the LSD experience revealed by multimodal neuroimaging , 2016, Proceedings of the National Academy of Sciences.

[20]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[21]  J. Halpern,et al.  Do hallucinogens cause residual neuropsychological toxicity? , 1999, Drug and alcohol dependence.

[22]  D. Araujo,et al.  Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. , 2015, Revista brasileira de psiquiatria.

[23]  K. Murnane,et al.  The behavioral pharmacology of hallucinogens. , 2008, Biochemical pharmacology.

[24]  D. Nutt,et al.  LSD modulates music-induced imagery via changes in parahippocampal connectivity , 2016, European Neuropsychopharmacology.

[25]  F. Vollenweider,et al.  Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis , 1997, Neuropsychopharmacology.

[26]  P. Anderer,et al.  Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. , 2002, British journal of clinical pharmacology.

[27]  F. Vollenweider,et al.  The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making , 2015, European psychiatry.

[28]  H. Isbell,et al.  Comparison of psilocin with psilocybin, mescaline and LSD-25 , 2004, Psychopharmacologia.

[29]  M. Liechti,et al.  Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies , 2017, Journal of psychopharmacology.

[30]  H. Emrich,et al.  The Pharmacology of Lysergic Acid Diethylamide: A Review , 2008, CNS neuroscience & therapeutics.

[31]  F. Vollenweider,et al.  The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation , 2017, Current Biology.

[32]  R. Strassman,et al.  Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.

[33]  Karl J. Friston,et al.  Broadband Cortical Desynchronization Underlies the Human Psychedelic State , 2013, The Journal of Neuroscience.

[34]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[35]  R. E. Belleville,et al.  Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. , 1956, A.M.A. archives of neurology and psychiatry.

[36]  M. Baggott,et al.  Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. , 2011, Drug and alcohol dependence.

[37]  D. Nutt,et al.  Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide , 2016, Journal of psychopharmacology.

[38]  M. Liechti,et al.  Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs) , 2015, Neuropharmacology.

[39]  M. Liechti,et al.  Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. , 2014, The international journal of neuropsychopharmacology.

[40]  S. Borgwardt,et al.  Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects , 2017, Translational Psychiatry.

[41]  David E. Nichols,et al.  Psychedelics , 2016, Pharmacological Reviews.

[42]  M. Liechti,et al.  Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans , 2015, The international journal of neuropsychopharmacology.

[43]  T. Passie,et al.  LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects , 2015, Journal of psychopharmacology.

[44]  M. Liechti,et al.  Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects , 2016, Journal of neuroendocrinology.

[45]  Matthew W. Johnson,et al.  Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population , 2015, Journal of psychopharmacology.

[46]  Peter J Hellyer,et al.  The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs , 2014, Front. Hum. Neurosci..

[47]  S. Unger,et al.  The experimental use of psychedelic (LSD) psychotherapy. , 1970, JAMA.

[48]  D. Nutt Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future , 2016, Journal of psychopharmacology.

[49]  M. Geyer,et al.  LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor , 2009, Psychopharmacology.

[50]  Matthew W. Johnson,et al.  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects , 2011, Psychopharmacology.

[51]  S. Borgwardt,et al.  LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality , 2016, Neuropsychopharmacology.

[52]  M. Liechti,et al.  Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. , 2017, Drug testing and analysis.

[53]  Franz X Vollenweider,et al.  Serotonin research: contributions to understanding psychoses. , 2008, Trends in pharmacological sciences.

[54]  D. Nutt,et al.  LSD enhances the emotional response to music , 2015, Psychopharmacology.

[55]  F. Vollenweider,et al.  Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors , 2012, Biological Psychiatry.

[56]  F. Vollenweider,et al.  Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation , 2017, Psychopharmacology.

[57]  J. Riba,et al.  Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study , 2012, PloS one.

[58]  E. Seifritz,et al.  Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations , 2015, Psychopharmacology.

[59]  R. Kellner,et al.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. , 1994, Archives of general psychiatry.

[60]  M. Liechti,et al.  Acute Effects of 3,4-Methylenedioxymethamphetamine and Methylphenidate on Circulating Steroid Levels in Healthy Subjects , 2014, Neuroendocrinology.

[61]  L. Hollister,et al.  Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures. , 1962, Comprehensive psychiatry.

[62]  R. Griffiths,et al.  Human hallucinogen research: guidelines for safety , 2008, Journal of psychopharmacology.

[63]  James Rucker,et al.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.

[64]  D. Nutt,et al.  A placebo-controlled investigation of synaesthesia-like experiences under LSD , 2016, Neuropsychologia.

[65]  M. Liechti,et al.  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens , 2016, European Neuropsychopharmacology.

[66]  M. Liechti,et al.  Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases , 2015, Analytical and Bioanalytical Chemistry.

[67]  Richard G. Wise,et al.  Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin , 2012, Proceedings of the National Academy of Sciences.

[68]  Matthew W. Johnson,et al.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. , 2015, Current drug abuse reviews.

[69]  F. Vollenweider,et al.  Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects , 2015, Biological Psychiatry.

[70]  K. Heekeren,et al.  Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers , 2005, Pharmacopsychiatry.

[71]  T. Passie,et al.  Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases , 2014, The Journal of nervous and mental disease.

[72]  F. Vollenweider,et al.  Phenomenology, Structure, and Dynamic of Psychedelic States. , 2016, Current topics in behavioral neurosciences.

[73]  Robert Leech,et al.  The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers , 2014, Front. Hum. Neurosci..

[74]  D. Nutt,et al.  The paradoxical psychological effects of lysergic acid diethylamide (LSD) , 2016, Psychological Medicine.

[75]  M. Liechti,et al.  Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects , 2017, Clinical Pharmacokinetics.

[76]  F. Vollenweider,et al.  Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers , 2015, Biological Psychiatry.

[77]  B. Schmidt,et al.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial , 2016, Journal of psychopharmacology.

[78]  Felix Hasler,et al.  Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies , 2011, Journal of psychopharmacology.

[79]  Matthew W. Johnson,et al.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction , 2014, Journal of psychopharmacology.

[80]  M. Liechti,et al.  Alterations of consciousness and mystical-type experiences after acute LSD in humans , 2016, Psychopharmacology.

[81]  J. Halpern,et al.  A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. , 2018, Current topics in behavioral neurosciences.

[82]  A. Feilding,et al.  LSD enhances suggestibility in healthy volunteers , 2014, Psychopharmacology.

[83]  J. Riba,et al.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years , 2016, Therapeutic advances in psychopharmacology.

[84]  D. Marona-Lewicka,et al.  Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action , 2007, Pharmacology Biochemistry and Behavior.

[85]  S. Borgwardt,et al.  Increased thalamic resting‐state connectivity as a core driver of LSD‐induced hallucinations , 2017, Acta psychiatrica Scandinavica.